This radiation and bio-detection technology developer reported its first-ever profit, significantly exceeding market expectations. Revenue surged 37%, driven by a landmark agreement with Siemens Healthineers.
The technology company has secured a new biosecurity contract from the UK Ministry of Defence and received additional CBRN detection orders from global customers, providing increased visibility on future revenue.
The technology company has received a $5m payment under its agreement with a major healthcare partner, strengthening its balance sheet and providing a foundation for sustainable growth.
The technology company has secured a £1.7m contract under the UK Government's Radiological Nuclear Detection Framework, affirming its leadership in the CBRN detection sector.
The technology company hosts a presentation for investors, providing an overview of its business and operations.
The scientific instruments company is hosting a capital markets day to discuss its growth strategy, including plans to scale the business to achieve revenues over £60m and a 30% EBITDA margin.
The technology company has announced a change in shareholding, with Polymer N2 Limited increasing its stake to 15.28%.
The technology company has issued new shares to satisfy the payment of accrued interest on a loan facility, improving its financial position.
The technology company has announced a change in major shareholding by a significant investor.
The scientific instruments company is hosting a capital markets day for investors and analysts to discuss its strategy and growth prospects.